+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immuno-Oncology Drugs Global Market Opportunities And Strategies To 2031

  • PDF Icon

    Report

  • 303 Pages
  • July 2022
  • Region: Global
  • The Business Research Company
  • ID: 5633492
This report describes and explains the global immuno-oncology drugs market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

The global immuno-oncology drugs market reached a value of nearly $67,882.2 million in 2021, having increased at a compound annual growth rate (CAGR) of 19.5% since 2016. The market is expected to grow from $67,882.2 million in 2021 to $116,237.0 million in 2026 at a rate of 11.4%. The market is then expected to grow at a CAGR of 10.0% from 2026 and reach $186,918.8 million in 2031.

Growth in the historic period in the immuno-oncology drugs market resulted from the rise in the number of cancer cases, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical R&D expenditure. The market was restrained by high cost of immuno-oncology therapies, low healthcare access, pricing pressures from regulators, high R&D costs, and patent expiration of drugs.

Going forward, increasing investment in immuno-oncology, rising focus on immunotherapy drugs for cancer treatment, product innovations through strategic collaborations and increasing geriatric population are expected to drive the market. Factors that could hinder the growth of the market in the future include side effects associated with immunotherapies and rising popularity of alternative therapies and natural remedies.

The immuno-oncology drugs market is segmented by type into Immune checkpoint inhibitors, immune system modulators, other monoclonal antibodies, cancer vaccines, and others. The other monoclonal antibodies segment was the largest segment of the immuno-oncology drugs market segmented by type, accounting for 40.3% of the total in 2021. Going forward, the others segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by type, at a CAGR of 26.8% during 2021-2026.

The immuno-oncology drugs market is also segmented by therapeutic application into melanoma, lung cancer, blood cancer, renal cell carcinoma, bladder cancer and other therapeutic application. The other therapeutic application was the largest segment of the immuno-oncology drugs market segmented by therapeutic application, accounting for 37.9% of the total in 2021. Going forward, the bladder cancer segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by therapeutic application, at a CAGR of 20.7% during 2021-2026.

The immuno-oncology drugs market is also segmented by end-users into hospitals, clinics, ambulatory surgical centers and others end user. The hospitals segment was the largest segment of the immuno-oncology drugs market segmented by end-users, accounting for 45.7% of the total in 2021. Going forward, hospitals segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by end-users, at a CAGR of 11.8% during 2021-2026.

North America was the largest region in the immuno-oncology drugs market, accounting for 48.3% of the total in 2021. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the immuno-oncology drugs market will be Middle East and South America where growth will be at CAGRs of 14.0% and 12.8% respectively during 2021-2026. These will be followed by Africa and Eastern Europe, where the markets are expected to register CAGRs of 12.5% and 12.2% respectively during 2021-2026.

The global immuno-oncology drugs market is highly consolidated with a small number of large players dominating the market. The top ten competitors in the market made up to 96.84% of the total market in 2020. Major players in the market include F. Hoffmann-La Roche, Merck & Co, Bristol-Myers Squibb, Amgen Inc, and Johnson & Johnson.

The top opportunities in the immuno-oncology drugs market segmented by type will arise in other monoclonal antibodies segment, which will gain $17,982.0 of global annual sales by 2026. The top opportunities in the immuno-oncology drugs market segmented by therapeutic application will arise in other therapeutic application segment, which will gain $15,867.8 million of global annual sales by 2026. The top opportunities in the immuno-oncology drugs market segmented by end-users will arise in hospitals segment, which will gain $23,174.2 million of global annual sales by 2026. The immuno-oncology drugs market size will gain the most in the USA at $22,184.1 million.

Market-trend-based strategies for the immuno-oncology drugs include companies should develop microneedle injector-based drugs to increase the bioavailability and eliminate side effects of the subcutaneous route, consider investing in developing personalized oncology drugs to treat specific patients, consider investing in acquisitions to increase market shares and expand their product portfolio offerings, focus efforts on the development of next-generation biologics to increase revenue and market share, focus on the development of antibody-drug conjugates to manufacture medicines for cancer treatment, invest in AI solutions, reduce R&D costs and save development time, invest in 3D printing devices to test new oncology drugs, opt for immune-oncology combination therapies to boost innovation and establish category leadership, and implement CAR-T therapies to boost innovations and establish category leadership.

Player-adopted strategies in the immuno-oncology drugs market include focusing on developing and launching new combinational drug therapies, improving presence in the immuno-oncology market through strategic partnerships, strengthening immune-oncology business through product licensing and acquisitions, and evaluating and advancing new technologies to change the treatment models and offer efficacious therapies in the field of immuno-oncology by creating strategic alliances.

To take advantage of the opportunities, the publisher reccomends the immuno-oncology drugs companies to focus on new product launches, focus on immuno-oncology combination therapies, expand in emerging markets, increase merger and acquisition activity, provide competitively priced offerings, focus on securing long-term supply contracts with healthcare institutions, offer value-based pricing, focus on educating consumers about immuno-oncology drugs and focus on the elderly population.


Frequently Asked Questions about the Global Immuno-Oncology Drugs Market

What is the estimated value of the Global Immuno-Oncology Drugs Market?

The Global Immuno-Oncology Drugs Market was estimated to be valued at $67882.2 Million in 2021.

What is the growth rate of the Global Immuno-Oncology Drugs Market?

The growth rate of the Global Immuno-Oncology Drugs Market is 10.7%, with an estimated value of $186918.8 Million by 2031.

What is the forecasted size of the Global Immuno-Oncology Drugs Market?

The Global Immuno-Oncology Drugs Market is estimated to be worth $186918.8 Million by 2031.

Who are the key companies in the Global Immuno-Oncology Drugs Market?

Key companies in the Global Immuno-Oncology Drugs Market include F. Hoffmann, La Roche Ltd., Merck & Co., Bristol, Myers Squibb Company and Johnson & Johnson.

Table of Contents

1. Immuno-Oncology Drugs Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
6.1. Segmentation By Geography
6.2. Segmentation By Type
6.3. Segmentation By Therapeutic Application
6.4. Segmentation By End Users
7. Immuno-Oncology Drugs Market Characteristics
7.1. Market Definition
7.2. Market Segmentation By Type
7.2.1. Immune Checkpoint Inhibitors
7.2.2. Immune System Modulators
7.2.3. Other Monoclonal Antibodies
7.2.4. Cancer Vaccines
7.2.5. Others
7.3. Market Segmentation By Therapeutic Application
7.3.1. Melanoma
7.3.2. Lung Cancer
7.3.3. Blood Cancer
7.3.4. Renal Cell Carcinoma
7.3.5. Prostate Cancer
7.3.6. Bladder Cancer
7.3.7. Others
7.4. Market Segmentation By End User
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Ambulatory Surgical Centers
7.4.4. Cancer Research Institutes
8. Immuno-Oncology Drugs Market Trends and Strategies
8.1. Increasing Usage of Microneedle Pills
8.2. Development Of Personalized Cancer Vaccines
8.3. Increase In Acquisition Activity Among Immuno-Oncology Drug Market Players
8.4. Development And Increasing Demand For Next-Generation Biologics
8.5. Investment In Artificial Intelligence For Oncology Drugs
8.6. Use Of 3D Printing To Test New Oncology Drugs
8.7. Immuno-Oncology Combination Therapies
8.8. CAR-T Cell Therapy
9. COVID Impact On The Immuno-Oncology Drugs Market
9.1. COVID-19 Pandemic Effects On Cancer Patients and Survivors
9.2. Clinical Trial Delays
9.3. Low Usage Of Drugs
9.4. Supply Chain Issues
9.5. Future Outlook
10. Global Immuno-Oncology Drugs Market Size And Growth
10.1. Market Size
10.2. Historic Market Growth, 2016 - 2021, Value ($ Million)
10.2.1. Drivers Of The Market 2016-2021
10.2.2. Restraints On The Market 2016 - 2021
10.3. Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
10.3.1. Drivers Of The Market 2021 - 2026
10.3.2. Restraints On The Market 2021 - 2026
11. Global Immuno-Oncology Drugs Market Segmentation
11.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.3. Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12. Immuno-Oncology Drugs Market, Regional And Country Analysis
12.1. Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12.2. Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13. Asia-Pacific Immuno-Oncology Drugs Market
13.1. Asia-Pacific Immuno-Oncology Drugs Market Overview
13.1.1. Region Information
13.1.2. Market Information
13.1.3. Background Information
13.1.4. Government Initiatives
13.1.5. Regulations
13.1.6. Regulatory Bodies
13.1.7. Major Associations
13.1.8. Taxes Levied
13.1.9. Corporate Tax Structure
13.1.10. Investments
13.1.11. Major Companies
13.2. Asia-Pacific Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.3. Asia-Pacific Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.4. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.5. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.6. Asia-Pacific Immuno-Oncology Drugs Market: Country Analysis
13.7. China Immuno-Oncology Drugs Market
13.8. China Immuno-Oncology Drugs Market Overview
13.8.1. Region Information
13.8.2. Market Information
13.8.3. Background Information
13.8.4. Government Initiatives
13.8.5. Regulations
13.8.6. Regulatory Bodies
13.8.7. Major Associations
13.8.8. Taxes Levied
13.8.9. Corporate Tax Structure
13.8.10. Investments
13.8.11. Major Companies
13.9. China Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.10. China Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.11. China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.12. China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.13. India Immuno-Oncology Drugs Market
13.14. India Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.15. India Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.16. India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.17. India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.18. Japan Immuno-Oncology Drugs Market
13.19. Japan Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.20. Japan Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.21. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.22. Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.23. Australia Immuno-Oncology Drugs Market
13.24. Australia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.25. Australia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.26. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.27. Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.28. Indonesia Immuno-Oncology Drugs Market
13.29. Indonesia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.30. Indonesia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.31. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.32. Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.33. South Korea Immuno-Oncology Drugs Market
13.34. South Korea Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.35. South Korea Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.36. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.37. South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14. Western Europe Immuno-Oncology Drugs Market
14.1. Western Europe Immuno-Oncology Drugs Market Overview
14.1.1. Region Information
14.1.2. Market Information
14.1.3. Background Information
14.1.4. Government Initiatives
14.1.5. Regulations
14.1.6. Regulatory Bodies
14.1.7. Major Associations
14.1.8. Taxes Levied
14.1.9. Corporate Tax Structure
14.1.10. Investments
14.1.11. Major Companies
14.2. Western Europe Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.3. Western Europe Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.4. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.5. Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.6. Western Europe Immuno-Oncology Drugs Market: Country Analysis
14.7. UK Immuno-Oncology Drugs Market
14.8. UK Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.9. UK Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.10. UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.11. UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.12. Germany Immuno-Oncology Drugs Market
14.13. Germany Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.14. Germany Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.15. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.16. Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.17. France Immuno-Oncology Drugs Market
14.18. France Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.19. France Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.20. France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.21. France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15. Eastern Europe Immuno-Oncology Drugs Market
15.1. Eastern Europe Immuno-Oncology Drugs Market Overview
15.1.1. Region Information
15.1.2. Market Information
15.1.3. Background Information
15.1.4. Government Initiatives
15.1.5. Regulations
15.1.6. Regulatory Bodies
15.1.7. Major Associations
15.1.8. Taxes Levied
15.1.9. Corporate Tax Structure
15.1.10. Investments
15.1.11. Major Companies
15.2. Eastern Europe Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
15.3. Eastern Europe Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
15.4. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15.5. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15.6. Eastern Europe Immuno-Oncology Drugs Market: Country Analysis
15.7. Russia Immuno-Oncology Drugs Market
15.8. Russia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
15.9. Russia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
15.10. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15.11. Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
16. North America Immuno-Oncology Drugs Market
16.1. North America Immuno-Oncology Drugs Market Overview
16.1.1. Region Information
16.1.2. Market Information
16.1.3. Background Information
16.1.4. Government Initiatives
16.1.5. Regulations
16.1.6. Regulatory Bodies
16.1.7. Major Associations
16.1.8. Taxes Levied
16.1.9. Corporate Tax Structure
16.1.10. Investments
16.1.11. Major Companies
16.2. North America Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
16.3. North America Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
16.4. North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
16.5. North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
16.6. North America Immuno-Oncology Drugs Market: Country Analysis
16.7. USA Immuno-Oncology Drugs Market
16.8. USA Immuno-Oncology Drugs Market Overview
16.8.1. Region Information
16.8.2. Market Information
16.8.3. Background Information
16.8.4. Government Initiatives
16.8.5. Regulations
16.8.6. Regulatory Bodies
16.8.7. Major Associations
16.8.8. Taxes Levied
16.8.9. Corporate Tax Structure
16.8.10. Investments
16.8.11. Major Companies
16.9. USA Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
16.10. USA Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
16.11. USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
16.12. USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
17. South America Immuno-Oncology Drugs Market
17.1. South America Immuno-Oncology Drugs Market Overview
17.1.1. Region Information
17.1.2. Market Information
17.1.3. Background Information
17.1.4. Government Initiatives
17.1.5. Regulations
17.1.6. Regulatory Bodies
17.1.7. Major Associations
17.1.8. Taxes Levied
17.1.9. Corporate Tax Structure
17.1.10. Investments
17.1.11. Major Companies
17.2. South America Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
17.3. South America Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
17.4. South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
17.5. South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
17.6. South America Immuno-Oncology Drugs Market: Country Analysis
17.7. Brazil Immuno-Oncology Drugs Market
17.8. Brazil Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
17.9. Brazil Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
17.10. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
17.11. Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
18. Middle East Immuno-Oncology Drugs Market
18.1. Middle East Immuno-Oncology Drugs Market Overview
18.1.1. Region Information
18.1.2. Market Information
18.1.3. Background Information
18.1.4. Government Initiatives
18.1.5. Regulations
18.1.6. Regulatory Bodies
18.1.7. Major Associations
18.1.8. Taxes Levied
18.1.9. Corporate Tax Structure
18.1.10. Investments
18.1.11. Major Companies
18.2. Middle East Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
18.3. Middle East Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
18.4. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
18.5. Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
19. Africa Immuno-Oncology Drugs Market
19.1. Africa Immuno-Oncology Drugs Market Overview
19.1.1. Region Information
19.1.2. Market Information
19.1.3. Background Information
19.1.4. Government Initiatives
19.1.5. Regulations
19.1.6. Regulatory Bodies
19.1.7. Major Associations
19.1.8. Taxes Levied
19.1.9. Corporate Tax Structure
19.1.10. Investments
19.1.11. Major Companies
19.2. Africa Immuno-Oncology Drugs Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
19.3. Africa Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
19.4. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
19.5. Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
20. Global Immuno-Oncology Drugs Market Competitive Landscape
20.1. Company Profiles
20.2. F. Hoffmann-La Roche Ltd. (Roche)
20.2.1. Company Overview
20.2.2. Products And Services
20.2.3. Business Strategy
20.2.4. Financial Overview
20.3. Merck & Co.
20.3.1. Company Overview
20.3.2. Products And Services
20.3.3. Business Strategy
20.3.4. Financial Overview
20.4. Bristol-Myers Squibb Company
20.4.1. Company Overview
20.4.2. Products And Services
20.4.3. Business Strategy
20.4.4. Financial Overview
20.5. Amgen Inc
20.5.1. Company Overview
20.5.2. Products And Services
20.5.3. Business Strategy
20.5.4. Financial Overview
20.6. Johnson & Johnson (J&J)
20.6.1. Company Overview
20.6.2. Products And Services
20.6.3. Business Strategy
20.6.4. Financial Overview
21. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market
21.1. Sanofi Acquired Amunix Pharmaceuticals Inc.
21.2. Takeda Yet To Acquire Adaptate Biotherapeutics
21.3. Takeda Acquired GammaDelta Therapeutics
21.4. Pfizer Acquired Trillium Therapeutics
21.5. Amgen Acquired Teneobio Inc.
21.6. True North Acquired Stake In Biocon Biologics Ltd.
21.7. PAG Acquired Stake In Hisun BioRay
21.8. Eli Lilly And Company Acquired Loxo Oncology, Inc.
21.9. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech
21.10. Bristol-Myers Squibb Acquired Celgene Corporation
21.11. Kashiv Pharma, LLC Acquired Adello Biologics
21.12. Takeda Pharmaceutical Company Limited Acquired Shire Plc
21.13. GlaxoSmithKline Plc Acquired Tesaro Inc.
22. Immuno-Oncology Drugs Market Opportunities And Strategies
22.1. Global Immuno-Oncology Drugs Market In 2026 - Countries Offering Most New Opportunities
22.2. Global Immuno-Oncology Drugs Market In 2026 - Segments Offering Most New Opportunities
22.3. Global Immuno-Oncology Drugs Market In 2026 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies
23. Immuno-Oncology Drugs Market, Conclusions And Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People
24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. Research Inquiries
24.5. About the Publisher
24.6. Copyright and Disclaimer

Executive Summary

Immuno-Oncology Drugs Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global immuno-oncology drugs market as it emerges from the COVID 19 shut down.



Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Description:

Where is the largest and fastest growing market for immuno-oncology drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The immuno-oncology drugs market global report answers all these questions and many more.


The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider immuno-oncology drugs market; and compares it with other markets.



The report covers the following chapters

  • Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
  • Report Structure - This section gives the structure of the report and the information covered in the various sections.
  • Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type, segmentation by therapeutic application, and segmentation by end users.
  • Market Characteristics - The market characteristics section of the report defines and explains the immuno-oncology drugs market. This chapter also defines and describes goods and related services covered in the report.
  • Trends And Strategies - This chapter describes the major trends shaping the global immuno-oncology drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
  • Impact of COVID-19 - This section describes the impact of COVID-19 on the immuno-oncology drugs market.
  • Global Market Size And Growth - This section contains the global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional Analysis - This section contains the historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values and growth and market share comparison by region.
  • Segmentation - This section contains the market values (2016-2031) and analysis for different segments.
  • Regional Market Size and Growth - This section contains the region’s market size (2021), historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
  • Competitive Landscape - This section covers details on the competitive landscape of the global immuno-oncology drugs market, estimated market shares and company profiles for the leading players.
  • Key Mergers And Acquisitions - This section gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
  • Conclusion and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for immuno-oncology drugs providers in terms of product offerings, geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope


Markets Covered:


  1. By Type: Immune Checkpoint Inhibitors; Immune System Modulators; Other Monoclonal Antibodies; Cancer Vaccines; Others
  2. By Therapeutic Application: Melanoma; Lung Cancer; Blood Cancer; Renal Cell Carcinoma; Bladder Cancer; Other Therapeutic Application
  3. By End-Users: Hospitals; Clinics; Ambulatory Surgical Centers; Others

Companies Mentioned:

F. Hoffmann-La Roche Ltd.; Merck & Co.; Bristol-Myers Squibb Company; Amgen Inc; Johnson & Johnson


Countries:

China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia


Regions:

Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa


Time series:

Five years historic and ten years forecast.


Data:

Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; immuno-oncology drugs indicators comparison.


Data segmentations:

country and regional historic and forecast data; market share of competitors; market segments.


Sourcing and Referencing:

Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Johnson & Johnson

Methodology

Loading
LOADING...